Recently, Baixi Ousi (Beijing) Biological Technology Co., Ltd. announced the completion of a multi-million RMB B+ round of financing led by Pine Capital, with participation from Xiamen High-Tech Investment and Saint-Novo Biopharm, while the existing shareholder, Sino Biological, continued to increase its investment. The funds raised in this round will be used to advance the Phase II clinical trials of BXOS110, a Class 1 innovative drug for treating ischemic stroke, as well as to file IND applications for two other Class 1 innovative drug products, BXOS116 and BXOS401, which are aimed at neural repair and regeneration during the stroke recovery period.
Baixi Ousi is a company focused on the field of neurological diseases, concentrating on the prevention and treatment of nerve damage throughout the entire stroke cycle, neuroprotection in ischemic and hemorrhagic strokes, brain edema, and nerve repair, among others. These areas have significant unmet clinical needs. The company possesses small molecule and peptide drug discovery platforms, in vitro molecular and cellular level drug screening platforms, and in vivo animal level efficacy evaluation platforms, as well as a complete system for drug design, screening, evaluation, CMC, and clinical research.
Baixi Ousi’s leading pipeline for neuroprotective agents in acute ischemic stroke has implemented a multi-faceted and multi-level patent layout globally, obtaining 36 domestic and international invention patents (including 11 patents in European validation countries). Currently, there are no similar products on the market worldwide. It has completed Phase I clinical trials and successfully advanced to Phase II clinical trials, becoming the second most advanced candidate drug internationally and the first in China targeting the same mechanism.
Tian Qiuping, Chairman of Baixi Ousi (Beijing) Biological Technology Co., Ltd., stated that the company will actively promote the clinical transformation of BXOS116 and BXOS401 for neural repair and regeneration during the recovery phase of stroke, achieving a pipeline layout covering the entire disease cycle of stroke and developing truly effective innovative drugs to address unmet clinical needs in the stroke field.